Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Heart Failure 2Cardiotoxicity 2Neoplasms 1Lymphoma 1

Interventions

Echocardiography 4sacubitril and valsartan sodium hydrate drug combination 3Standard of Care 3Nutrition Assessment 3Exercise 3Electrocardiography 3Carvedilol 3dapagliflozin 2Surveys and Questionnaires 2Spironolactone 2Rituximab 2Lenalidomide 2Ivabradine 2Control Groups 2Blood Specimen Collection 2Atorvastatin 2Adrenergic beta-Antagonists 2ziprasidone 1pertuzumab 1pegfilgrastim 1obinutuzumab 1nicotinamide-beta-riboside 1empagliflozin 1candesartan 1acalabrutinib 1Zolpidem 1Watchful Waiting 1Warfarin 1Vincristine 1Vecuronium Bromide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Heart Failure × Ivabradine × Clear all
NCT04030546 2019-12-18

Ivabradine to Prevent Anthracycline-induced Cardiotoxicity

Vilnius University

Phase 3 Unknown
128 enrolled

Heart Failure, Cardiotoxicity

NCT03650205 2019-04-02

IPAC

University of Sao Paulo

Phase NA Unknown
160 enrolled

Heart Failure, Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡